Optimal second stage duration in nulliparas: why don’t we use morbidity to guide a cut-off? - 08/01/23
Doi : 10.1016/j.ajog.2022.11.1190
Nandini Raghuraman 1, Candice Woolfolk 2, Sindhu K. Srinivas 3, Antonina I. Frolova 4, Lorie M. Harper 5, Aaron B. Caughey 6, Alan T. Tita 7, Methodius G. Tuuli 8, Alison G. Cahill 9
1 Barnes Jewish Hospital, St. Louis, MO
2 Washington University in St.Louis, St. Louis, MO
3 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
4 Washington University School of Medicine, St. Louis, MO
5 University of Texas Dell Medical School, Austin, TX
6 Oregon Health and Science University, Portland, OR
7 Center for Women’s Reproductive Health, University of Alabama at Birmingham, Birmingham, AL
8 Women & Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, East Greenwich, RI
9 University of Texas at Austin, Dell Medical School, Austin, TX
1109
Le texte complet de cet article est disponible en PDF.Plan
© 2022
Publié par Elsevier Masson SAS.
Vol 228 - N° 1S
P. S711 - janvier 2023 Retour au numéro
Article précédent
- Prenatal cardiac predictors of outcome in severe twin-twin transfusion (Stage IV TTTS): largest center experience
- Mounria Habli, Kholoud Arab, Braxton Forde, Mallory Hoffman, David McKinney, Kara B. Markham, Jose Peiro, Foong Lim
- Pregnancy outcomes in women with elevated and stage I blood pressures after 20 weeks gestation
- Natalia Parra, Sbaa Syeda, Yijia Zhang, Uma M. Reddy, Natalie Bello, Nikolas Bletnisky, Whitney A. Booker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?